Farther Finance Advisors LLC Has $4.72 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Farther Finance Advisors LLC boosted its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 37.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 69,344 shares of the company's stock after purchasing an additional 19,061 shares during the period. Farther Finance Advisors LLC's holdings in Novo Nordisk A/S were worth $4,717,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Victory Capital Management Inc. raised its stake in shares of Novo Nordisk A/S by 58.5% during the fourth quarter. Victory Capital Management Inc. now owns 62,897 shares of the company's stock valued at $5,410,000 after acquiring an additional 23,223 shares during the last quarter. Bryn Mawr Capital Management LLC raised its stake in shares of Novo Nordisk A/S by 358.8% during the fourth quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company's stock valued at $3,346,000 after acquiring an additional 30,420 shares during the last quarter. DSM Capital Partners LLC raised its stake in shares of Novo Nordisk A/S by 16.7% during the fourth quarter. DSM Capital Partners LLC now owns 2,007,412 shares of the company's stock valued at $172,678,000 after acquiring an additional 286,912 shares during the last quarter. Channing Global Advisors LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at $354,000. Finally, Compagnie Lombard Odier SCmA raised its stake in shares of Novo Nordisk A/S by 5.0% during the fourth quarter. Compagnie Lombard Odier SCmA now owns 67,745 shares of the company's stock valued at $5,827,000 after acquiring an additional 3,200 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on NVO shares. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They set an "underperform" rating for the company. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. Guggenheim cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Finally, BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a research report on Thursday, April 17th. Two analysts have rated the stock with a sell rating, six have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Stock Down 1.4%

NYSE:NVO traded down $1.15 during trading hours on Friday, reaching $79.90. The company had a trading volume of 7,465,072 shares, compared to its average volume of 7,025,617. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The firm has a market cap of $358.57 billion, a price-to-earnings ratio of 24.29, a P/E/G ratio of 0.90 and a beta of 0.66. The business's 50-day simple moving average is $66.93 and its two-hundred day simple moving average is $80.00. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 EPS for the quarter, hitting analysts' consensus estimates of $0.92. The business had revenue of $11.87 billion during the quarter. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. On average, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.